Singapore HSA Becomes the World's First Regulator to Reach WHO Maturity Level 4 for Medical Devices (10 March 2026)

At a glance

On 10 March 2026 the Health Sciences Authority (HSA) of Singapore announced that it has become the first national regulatory authority in the world to be designated at Maturity Level 4 (ML4) — the highest level of the World Health Organization (WHO) framework for medical device regulatory systems.

• The recognition reflects HSA's performance across both pre-market and post-market medical device oversight and positions HSA as a global reference regulatory authority that other authorities can rely on.
• HSA is expanding its economic role through a new industry development function and further refinement of its regulatory framework to support biomedical innovation and industry growth.
• The Ministry of Health (MOH) and HSA jointly issued the revised Artificial Intelligence in Healthcare Guidelines (AIHGle 2.0), and HSA launched a beta risk classification tool for medical devices.
• For medical device manufacturers, Singapore's appeal as a gateway to ASEAN markets is strengthened: products registered with HSA may move faster into other global markets, with potential consequences for registration strategy and clinical evaluation pathways.

Full translation of the HSA announcement

HSA becomes the first national regulator globally to achieve WHO Maturity Level 4 for medical devices

The Health Sciences Authority (HSA) has become the first national regulatory authority in the world to reach Maturity Level 4 (ML4), the highest level of the World Health Organization (WHO) framework for medical device regulatory systems. The announcement was made by Mr Ong Ye Kung, Singapore's Minister for Health and Minister-in-charge of Social Policy, on 10 March 2026 at the opening of the 29th session of the International Medical Device Regulators Forum (IMDRF) in Singapore.

The WHO recognition reflects HSA's strong capability and high credibility in carrying out its pre-market and post-market medical device regulatory functions, enabling it to serve as a global reference regulatory authority whose decisions other regulators can trust to protect public health and safety.

Long-standing international recognition of HSA's regulatory system

Over the years, HSA's regulatory system has been internationally recognised as operating at an advanced level of performance, including:

• WHO stringent regulatory authority: since 2023, WHO has recognised HSA as a stringent regulatory authority for high-risk in vitro diagnostic (IVD) devices. This means high-risk IVDs registered with HSA may be eligible for an abbreviated assessment pathway under the WHO Prequalification programme, enabling faster access to global markets.
• Medicines regulatory system: in 2022, HSA became the first regulatory authority in the world to reach WHO Maturity Level 4 (the highest level) and was among the first three authorities to be listed as a WHO-Listed Authority (WLA). This reflects recognition of advanced regulatory performance globally, ensuring that medicines in Singapore meet high standards of safety, efficacy and quality.

Minister Ong Ye Kung also set out HSA's expanded economic role and how it will create economic value for Singapore's biomedical ecosystem.

HSA's expanded economic role and overall value proposition for industry

HSA's internationally recognised regulatory excellence anchors clinical development and product regulation, positioning Singapore as a key gateway for market access to health products and medical innovations, both locally and globally. This in turn supports the growth and development of the biomedical industry, a major contributor to Singapore's economy.

This is also about preparing for the future in a rapidly evolving health and medical technology landscape driven by artificial intelligence, precision medicine and next-generation diagnostics. To broaden its economic role, HSA will establish an industry development function that offers industry a holistic value proposition, and will refine its regulatory framework:

• (i) Research, Innovation and Enterprise (RIE) plans comprise a series of rolling five-year investments, with the latest plan, RIE2030, allocating S$37 billion (approximately US$29 billion) over the next five years. One of the key investment areas is Human Health and Potential. Through sustained investment, Singapore has built strong biomedical and biomanufacturing capabilities. HSA will work with universities, academic medical centres, hospitals and the Agency for Science, Technology and Research (A*STAR) to strengthen the biomedical innovation pipeline and generate impactful clinical applications.
• (ii) Collaboration across the innovation ecosystem: HSA will work closely with A*STAR, the Economic Development Board (EDB) and Enterprise Singapore (EnterpriseSG) to offer global and local biomedical companies a more comprehensive value proposition. International biomedical companies establishing operations in Singapore can expect a rigorous yet efficient registration process. With A*STAR, HSA will anchor translational research and industry-relevant innovation; with EDB, it will support efforts to attract manufacturing, R&D and regional headquarters investments to Singapore. This will help sustain Singapore's biopharmaceutical manufacturing output, which has doubled over the past two decades to S$13.9 billion in 2023, and its medical technology manufacturing output, which grew about tenfold from S$1.8 billion in 2003 to S$18.9 billion in 2023. For local companies, collaboration with EnterpriseSG will help facilitate regional and global market access and deepen cooperation with biomedical multinational companies based in Singapore.
• (iii) Clinical development: Singapore actively supports clinical trials. With a well-regarded and trusted regulatory and clinical ecosystem, Singapore can participate in multicentre clinical trial networks to support companies seeking to validate their innovations. About 100 industry-sponsored clinical trials are initiated in Singapore each year. HSA will continue to work with other public sector agencies, such as the Consortium for Clinical Research and Innovation, Singapore (CRIS), to strengthen clinical trial capabilities and increase this number.
• (iv) Coordinated pathways with the wider health system: among MOH agencies, HSA will work with the Agency for Care Effectiveness (ACE) and the public healthcare clusters to explore coordinated pathways that facilitate regulatory approval, health technology assessment and clinical development simultaneously, for products addressing Singapore's priority disease areas, including cardiovascular disease, diabetes and metabolic disorders.

Advancing the regulatory framework to support emerging technologies

HSA will continue to advance its regulatory capabilities to embrace emerging technologies, keeping Singapore at the forefront of innovation while maintaining the highest safety standards. This approach creates a competitive advantage for companies that choose Singapore as their base.

On 10 March 2026, MOH and HSA jointly developed and issued the revised Artificial Intelligence in Healthcare Guidelines (AIHGle 2.0). Building on the 2021 framework, AIHGle 2.0 addresses developments in artificial intelligence, such as generative artificial intelligence, and clarifies that such technologies should augment and empower healthcare professionals to improve patient care. The updated guidelines will help healthcare institutions build and implement clinically safe and effective solutions with patient safety at the core. Key updates in AIHGle 2.0 include: (a) stronger accountability through clearer responsibilities for key stakeholders; (b) greater trust through transparency guidance that supports informed decision-making; and (c) updated guidance on deployment, such as risk assessment and mitigation. The guidelines will be updated periodically in line with developments and new technologies to provide appropriate guidance.

Beyond regulating such technologies, HSA will progressively adopt them to create value for industry partners. From today, HSA has launched a risk classification tool for medical devices, available to industry partners to test and provide feedback. This beta tool provides automated guidance on preliminary risk classification estimates during product development.

Connecting healthcare, regulatory systems and industry

The 29th session of the IMDRF is being held in Singapore from 9 to 13 March 2026, attracting more than 400 participants, including regulators and industry experts from around the world, to discuss key developments in medical device regulation and technology. The forum is organised by HSA, which is also the current IMDRF Chair. As Chair, HSA continues to build meaningful bridges between regulatory systems and industry, fostering innovation while ensuring patient safety remains paramount.

Associate Professor (Dr) Cai Jingping, HSA's Chief Executive Officer and Deputy Director-General of Health Regulation at MOH, said: "We are deeply honoured that WHO has designated HSA at Maturity Level 4 for medical device regulatory systems, and that we are the first country in the world to receive this recognition. This achievement coincides with HSA expanding its economic role for the benefit of the biomedical industry and refining our regulations to support the adoption of more healthcare innovations, such as artificial intelligence, in healthcare. HSA will continue to engage and partner with industry and its associations in this expanded economic agenda and regulatory work. We hope to use this forum to bring regulators and industry together so that patients around the world can access the latest and safest medical devices for the treatment of various health conditions."

Health Sciences Authority, Singapore — 10 March 2026. A PDF version of the announcement is available from HSA.

Source and scope note

Source authority: Health Sciences Authority (HSA), Singapore. Original date: 10 March 2026. This article is compiled and translated from HSA public information: https://www.hsa.gov.sg/announcements/imdrf/. Formal requirements are subject to the latest official publications of the regulatory authority.

AIMEILI regulatory interpretation

This is a regulatory-system development rather than a product-specific rule change, but it carries direct strategic implications for registration planning.

First, on registration pathways: with HSA recognised as a global reference authority, HSA assessment outcomes may gain broader mutual recognition or simplified acceptance among WHO and other authorities that rely on HSA. For companies planning to enter ASEAN markets or seeking WHO prequalification, HSA registration may become an accelerating route. This is particularly relevant for high-risk IVDs, where HSA's status as a WHO stringent regulatory authority can open an abbreviated WHO prequalification assessment pathway.

Second, on classification and technical documentation: HSA's new risk classification tool provides preliminary classification estimates during product development, which can help companies define the regulatory route early. Where a device incorporates artificial intelligence, the revised AIHGle 2.0 sets expectations on transparency, allocation of responsibility and risk mitigation; companies should compare these expectations with other jurisdictions' requirements so that clinical evaluation and technical documentation remain compatible across markets.

Third, on quality systems and post-market maintenance: an ML4-rated system implies consistently high expectations for adverse event reporting, inspections and safety updates. Manufacturers should ensure that the quality system supporting an HSA registration can sustain ongoing conformity, and should consider alignment with ISO 13485 and the data-integrity expectations of downstream authorities that may rely on HSA outputs.

Fourth, on operational presence: HSA's expanded economic role and its collaboration with A*STAR, EDB and EnterpriseSG may ease the path for companies establishing R&D, manufacturing or regional headquarters in Singapore, and coordinated clinical trial networks can shorten product validation. Companies should still plan for differences from other jurisdictions, including clinical evidence acceptance criteria, English labelling requirements and the need for a local representative.

Business impact for medical device companies

• Gateway value increases: Singapore becomes a more credible first-entry market for ASEAN and for markets that look to reference-authority decisions.
• Registration sequencing: companies may consider placing HSA submission earlier in the global roll-out sequence, particularly for high-risk IVDs where WHO prequalification is a commercial objective.
• Technical file design: documentation should be structured to serve HSA, WHO prequalification and IMDRF-aligned expectations simultaneously, reducing rework across countries.
• Post-market readiness: higher maturity expectations translate into stronger scrutiny of vigilance processes, change notification and field safety corrective action capability.
• Emerging technology portfolio: products with artificial intelligence components require an explicit compliance position on transparency, accountability and risk mitigation, reflected in the technical file and labelling.

Documents to review first

Updates of this kind should not be treated as general industry news. Companies should first determine whether the information concerns regulatory policy, guidance and standards, recall and safety, product performance, quality systems or post-market oversight, because each affects registration pathways, technical documentation, labelling, risk management and market maintenance differently.

• Intended purpose and indications for use, and the classification rationale
• ISO 13485 certification and quality system documentation
• Risk management file and performance verification and validation data
• Clinical evaluation or clinical evidence
• Labels, instructions for use and language localisation
• Authorisation documents, local representative arrangements and existing registration certificates

Common risks

• Unclear or unsupported classification decisions
• Incomplete evidence chains between claims, verification data and clinical evidence
• Labels and instructions for use not localised for the target market
• Unclear allocation of responsibilities with the local representative
• Insufficient post-market maintenance and change-management planning

FAQ

Can the 10 March 2026 ML4 recognition be used directly as a basis for a regulatory submission?

No. The recognition is a system-level designation of the HSA regulatory framework; it does not replace the specific requirements of any target market. Formal submissions must still be based on the latest requirements of the target authority, the classification outcome for the specific device and the manufacturer's own documentation.

What should companies do first after reading this update?

Start with a documentation gap assessment to confirm whether the update affects the registration pathway, technical file, labelling, quality system or post-market maintenance for the affected products.

Does the announcement change submission requirements for devices already registered with HSA?

No immediate change to individual certificates is stated. However, the announcement signals continued strengthening of pre-market and post-market oversight, so holders should verify that vigilance, change notification and labelling arrangements remain current.

Editorial review and scope of application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI International Medical Device Registration Project Team.

Source principles: official regulatory authorities, international organisations, standards bodies and published regulations take priority; industry media and project experience are used only as supporting judgement.

Scope of application: this article supports preliminary understanding, document preparation and project planning. It does not replace the formal requirements of the target regulatory authority, testing conclusions or legal advice.